Karachi: GlaxoSmithKline Pakistan Limited (GSK) has announced a sterling performance for the first nine months of 2025, reporting a profit after taxation of Rs. 6.23 billion, a significant 74% increase compared to the Rs. 3.58 billion earned in the same period last year. This robust growth underscores the company’s successful strategy in a gradually stabilizing Pakistani economy.
The company’s earnings per share (EPS) surged to Rs. 19.57, up from Rs. 11.25 in 2024, making it a highly profitable period for its shareholders. This impressive bottom-line growth was fueled by a strong top-line performance, with net sales reaching Rs. 44.49 billion. A key driver was a substantially improved gross margin, which expanded to 35.8% from the previous period, attributed to strategic price increases and sustained profitability measures.
In their report to shareholders, the Board of Directors highlighted that the company maintained a sharp focus on enhancing operational efficiency and making strategic investments in key business areas. This disciplined approach resulted in operating expenses increasing by only a modest 1.6% relative to sales, ensuring that a larger portion of revenue translated into profit.
Despite the positive results, the company acknowledged ongoing economic headwinds, including risks from higher tariffs, inflationary pressures, and fiscal challenges. The directors also expressed confidence in the company’s resilience, emphasizing continued collaboration with stakeholders and investment in human capital to foster innovation.
The financial position remained strong, with total assets growing to Rs. 51.05 billion as of September 30, 2025. The board has also rewarded shareholders, distributing both a final dividend for 2024 and an interim dividend for 2025. With a solid operational foundation and a clear strategic direction, GSK Pakistan appears well-positioned to navigate the future economic landscape while continuing its mission of addressing the healthcare needs of the country.
